

Executive Summary

This document provides a guide to the Nagoya Protocol with an explanation of the key points and objectives set out within the Protocol.

The Nagoya Protocol entered into force on 12 October 2014 and aims to implement the third objective of the Convention on Biological Diversity (CBD), namely the fair and equitable sharing of benefits arising out of the utilisation of genetic resources. In accordance with the Nagoya Protocol, parties are placed under an obligation to establish legislative, administrative and/or political measures regarding the access to genetic resources.

Ultimately, the Nagoya Protocol aims to prevent bio-piracy. Bio-piracy is the commercial or academic development of genetic resources by a country or organisation without obtaining prior consent from, or providing fair compensation to, the people or country where the genetic resource was first discovered.

Key points of the Protocol

- The Nagoya Protocol relates to the utilisation of genetic resources. A genetic resource is defined as any nonhuman genetic resource. 'Utilisation' refers to research and development on the genetic and/or biochemical composition of genetic resources. The Protocol, therefore, relates to both commercial and academic research.
- The Nagoya Protocol gives provider countries the rights to control access to genetic resources found within their jurisdiction. The aim of this is to re-establish a provider country's control over these resources. There are 2 categories of provider country:

- An originating country where the genetic resource exists in situ, i.e. a country in which the genetic resource exists in its natural habitat.
- An originating country where the genetic resource exists
 ex situ, i.e. a country in which the genetic resource
 exists outside of its natural habitat. A country falling
 within this category must have obtained the genetic
 resource from an originating country under the CBD.
- The burden is placed on the user, for example a researcher, to show that the genetic resource on which they are conducting research was legally obtained in accordance with the Nagoya Protocol. In order to do this, a user must:
 - Obtain the prior informed consent of a providing country (i.e. the country where the genetic resource exists in situ) before access to a genetic resource is permitted
 - Provide a fair and equitable share of the benefits which arise from utilisation of the genetic resources. Such sharing shall be upon mutually agreed terms. The benefits can be either commercial or non-commercial, including the sharing of data or a transfer of intellectual property rights.

If a user cannot show that a genetic resource has been accessed in accordance with the provisions of the Nagoya Protocol, all work utilising that genetic resource must be halted.

The effect of the Nagoya Protocol is to make it illegal to perform research and development on a genetic resource that has not been accessed in accordance with the Nagoya Protocol.





Who is party to the Nagoya Protocol?

1.	Albania	2013-01-29	24.	Guatemala	2014-06-18	46.	Mongolia
2.	Belarus	2014-06-26	25.	Guinea	2014-10-07	47.	Mozambiqu
3.	Benin	2014-01-22	26.	Guinea-Bissau	2013-09-24	48.	Myanmar
4.	Bhutan	2013-09-30	27.	Guyana	2014-04-22	49.	Namibia
5.	Botswana	2013-02-21	28.	Honduras	2013-08-12	50 .	Niger
6.	Burkina Faso	2014-01-10	29.	Hungary	2014-04-29	51.	Norway
7.	Burundi	2014-07-03	30.	India	2012-10-09	52 .	Pakistan
8.	Cambodia	2015-01-19	31.	Indonesia	2013-09-24	53 .	Panama
9.	Comoros	2013-05-28	32.	Jordan	2012-01-10	54.	Peru
10.	Congo	2015-05-14	33.	Kazakhstan	2015-06-17	55.	Philippines
11.	Côte d'Ivoire	2013-09-24	34.	Kenya	2014-04-07	56 .	Rwanda
12.	Croatia	2015-09-02	35.	Kyrgyzstan	2015-06-15	57 .	Samoa
13.	Cuba	2015-09-17	36.	Lao People's		58.	Senegal
14.	Democratic			Democratic Republic	2012-09-26	59.	Seychelles
	Republic of the Congo	2015-02-04	37.	Lesotho	2014-11-12	60.	Slovakia
15.	Denmark	2014-05-01	38.	Liberia	2015-08-17	61.	South Afric
16.	Djibouti	2015-10-01	39.	Madagascar	2014-07-03	62.	Spain
17.	Dominican Republic	2014-11-13	40.	Malawi	2014-08-26	63.	Sudan
18.	Egypt	2013-10-28	41.	Marshall Islands	2014-10-10	64.	Switzerlan
19.	Ethiopia	2012-11-16	42.	Mauritania	2015-08-18	65.	Syrian Aral
20.	European Union	2014-05-16	43.	Mauritius	2012-12-17	66.	Tajikistan
21.	Fiji	2012-10-24	44.	Mexico	2012-05-16	67.	Togo
22.	Gabon	2011-11-11	45.	Micronesia	2012 01 20	68.	Uganda
23.	Gambia (the)	2014-07-03		(Federated States of)	2013-01-30		United Aral

Since entering into force on 12 October 2014, 73 parties have ratified the Nagoya Protocol, including the European Union

46.	Mongolia	2013-05-21
47.	Mozambique	2014-07-07
48.	Myanmar	2014-01-08
49.	Namibia	2014-05-15
50.	Niger	2014-07-02
51.	Norway	2013-10-01
52 .	Pakistan	2015-11-23
53.	Panama	2012-12-12
54.	Peru	2014-07-08
55.	Philippines	2015-09-29
56.	Rwanda	2012-03-20
57.	Samoa	2014-05-20
58.	Senegal	2016-03-03
59.	Seychelles	2012-04-20
60.	Slovakia	2015-12-29
61.	South Africa	2013-01-10
62.	Spain	2014-06-03
63.	Sudan	2014-07-07
64.	Switzerland	2014-07-11
65.	Syrian Arab Republic	2013-04-05
66.	Tajikistan	2013-09-04
67.	Togo	2016-02-10
68.	Uganda	2014-06-25
69.	United Arab Emirates	2014-09-12
70.	United Kingdom of Great Britain and Northern Ireland	2016-02-22
71.	Uruguay	2010-02-22
71.	Vanuatu	2014-07-14
	Viet Nam	2014-07-01
13.	AICT MAIII	2014-04-23

Implementation of the Nagoya Protocol in the European Union (EU)

The Nagoya Protocol fully entered into force in the EU on 12 October 2014 under EU Reg. 511/2014. The rules for the implementation of Reg. 511/2014 regarding the registration of the collection of genetic resources, monitoring user compliance and best practices, entered into force on 9 November 2015 under EU Reg. 2015/1866.

The above EU Regulations are directly applicable to all EU member states. The regulations ensure a uniform application of the law across all states. The regulations apply to genetic resources over which EU member states exercise sovereign rights, and to 'traditional knowledge' associated with genetic resources falling within the scope of the Nagoya Protocol. For the regulations to apply, the genetic resources must be accessed by an EU member state after entry into force of the Nagoya Protocol for the EU.

Compliance with the Nagoya Protocol

Implementation of the Nagoya Protocol is to be co-ordinated by a newly formed international body known as the Access and Benefits Sharing (ABS) Clearing House.

The following steps are required to be taken in order to comply with the Nagoya Protocol:

- A provider country informs the clearing house of its national provisions with regards to access and benefits sharing (ABS) information. The clearing house will keep this information up-to-date.
- The clearing house acts as an intermediary. If a user
 wishes to access a genetic resource from a provider
 country, the user should contact the clearing house for
 details of how to agree mutually agreed terms with the
 provider country.
- 3. From the information provided by the clearing house, the user contacts the relevant government department in the provider country and obtains permission for either non-commercial or commercial use (details can be made confidential and, therefore, not open to inspection by third parties). If non-commercial use is initially agreed, terms can be re-negotiated at a later date if commercialisation appears likely.
- 4. The provider country issues to the user a national permit.

 Additionally, the provider country files the national permit at the clearing house.
- An internationally recognised certificate of compliance (IRCC) is issued electronically by the clearing house.
 The IRCC acts as proof that the genetic resource has been accessed in accordance with the Nagoya Protocol.

- 6. Proof of compliance with the Nagoya Protocol must be issued when certain events are triggered. Such events include, receipt of research funding, commercialisation of a product and applying for market approval in the EU. Compliance can be proved by presenting the IRCC when required.
- 7. Details of the triggering event are communicated by the user to the clearing house which in turn contacts the provider country to report on the progress of the research and development of their genetic resources. This step gives the provider country an opportunity to negotiate new terms in light of the recent events, e.g. a commercialisation agreement if the initial agreement was only for noncommercial use.

Obligations of users

Users of genetic resources or traditional knowledge are obliged to exercise due diligence to ascertain that:

- any genetic resources and traditional knowledge utilised by the user has been accessed from a provider country party to the Nagoya Protocol in accordance with the applicable access and benefit-sharing legislation or requirements, and
- mutually agreed terms between the user and the provider country result in fair and equitable benefits to both parties, in accordance with applicable access and benefit-sharing legislation or requirements.

IRCC - Seek, keep and transfer procedure

The IRCC is issued for the purpose of the above obligations. A user is required to seek, keep and transfer to subsequent users the IRCC as evidence that the genetic resource it covers has been accessed in accordance with the Nagoya Protocol. The IRCC also shows that mutually agreed terms have been established between the user and a competent authority within the provider country. Further, any information relating to the content of the mutually agreed terms which is not contained in the IRCC must also be part of the 'seek, keep and transfer' procedure of the user.

If the relevant IRCC is not yet available, the user must seek, keep and transfer the following information and documents related to:

- date and place of access of the genetic resources or traditional knowledge;
- a description of the genetic resources or traditional knowledge utilised;



- the source from which the genetic resources or traditional knowledge were directly obtained;
- any subsequent users of the genetic resources or traditional knowledge;
- details regarding the presence or absence of rights and obligations pertaining to access and benefit-sharing, including any rights and obligations relating to subsequent applications and commercialisation;
- access permits, if applicable; and
- any information comprised in the mutually agreed terms and benefit-sharing agreements.

If the above information is found to be insufficient or there are legal uncertainties to the access and utilisation of the genetic resources, a user shall obtain an access permit (or equivalent) and establish mutually agreed terms with the provider country. If this is not achieved, utilisation must be discontinued by the user.

Further obligations

 Users must keep the information relevant to access and benefit-sharing for 20 years after the end of the period of utilisation.

- All recipients of research funding which involves the utilisation of genetic resources and traditional knowledge will be requested by the EU Member States to declare due diligence was exercised in accordance with the obligations of the users under EU Reg. 511/2014.
- At the final stage of development of a product developed via the utilisation of genetic resources or traditional knowledge, users must declare to the competent national authority that they have fulfilled the obligations of the users set by the EU regulations 511/2014 and 2015/1866. The declaration can take the form of presenting the IRCC to the competent national authority. If the IRCC is not available, the above-mentioned alternative information will suffice.

Register of collections

An internet-based register of collections is to be established within the EU in accordance with EU regulations. The register will comprise sets of collected samples of genetic resources and related information that is accumulated and stored. A user who obtains a genetic resource from a collection included in the register shall be deemed to have exercised due diligence in accordance with the relevant EU regulations.

Compliance checks

According to the EU regulations, the competent national authorities shall carry out effective, proportionate, and dissuasive checks to inspect whether users comply with the

obligations of the Nagoya Protocol. Compliance checks may include:

- Examination of the measures taken by a user to fulfil his obligations
- Examination of documentation and records which should demonstrate the users exercise of due diligence
- On-the-spot checks

If deficiencies are noted by the competent national authority, a notice of remedial action or a notice of measures to be implemented will be issued to the user.

Penalties for non-compliance

Each EU member state shall put forward effective, proportionate and dissuasive penalties which will be applicable to infringements of the obligations of users under the EU regulations which set out the Nagoya Protocol.

As the penalties are made at the discretion of each EU member state, violating the obligations of the user may have different consequences in different member states.

Penalties in the UK

Enforcement of the EU regulations relating to the Nagoya Protocol in the UK is the responsibility of the Department for Environment, Food and Rural Affairs (DEFRA). Compliance checks and monitoring will be handled by the National Measurements Office.

DEFRA have indicated that a fine of up to £250,000 and a maximum of two years in prison will be the appropriate penalties for severe cases of wilful non-compliance.

The effect of the Nagoya Protocol on patents

It is not yet known whether a violation of the aforementioned obligations will have consequences regarding the grant of a patent or the possible exploitation of a patent. Further, it is not yet known what the consequences, if any, will be.


However, it is predicted that competitors or other third parties will attempt to attack a patent if it is believed the patent owners have violated their obligations to the Nagoya Protocol. It is, therefore, of upmost importance that patentees and researchers exercise the required due diligence and take their obligations under the Nagoya Protocol (and relevant EU regulations) extremely seriously.

European Patents

The European Patent Convention (EPC) provides an autonomous legal system according to which European patents are granted. Currently, there are no plans to amend the EPC, or the respective rules, in response to the Nagoya Protocol. However, it is expected that the Nagoya Protocol and its corresponding EU regulations will at the minimum be taken into consideration with regard to the future grant of European patents.

Practical actions to be taken

- 1. Ensure existing genetic resources are sufficiently documented as having been accessed before the date of entry into force of the Nagoya Protocol in the EU (i.e. before 14 October 2014).
 - The Nagoya Protocol will not have retroactive effect in the EU. Hence, genetic
 resources shown to be accessed before the Nagoya Protocol will not be required
 to comply with the EU regulations which set out the Protocol in the EU.
- 2. Take action to ensure administrative systems are in place to make certain any new genetic resources are documented in compliance with the Nagoya Protocol.
- 3. Carry out internal training to make employees aware of the Nagoya Protocol and the obligations of users of any genetic resources.
 - Ensure employees understand that legal possession of a genetic resource does not necessarily imply that person has the right to do any work on or with that resource.
- 4. Be aware of the origin of any genetic resources you might wish to use for the purposes of research and development.





If you would like further advice on the Nagoya Protocol, how it may impact your business, or advice on any other aspects of intellectual property, please do not hesitate to get in contact.

TO BOOK YOUR FREE CONSULTATION PLEASE CONTACT



Ben Appleton
ben.appleton@wilsongunn.com
0121 236 1038

MANCHESTER OFFICE

5th Floor Blackfriars House The Parsonage Manchester M3 2JA United Kingdom

manchester@wilsongunn.com Tel: 0161 827 9400 Fax: 0161 832 4905

LONDON OFFICE

Central Court 25 Southampton Buildings London WC2A 1AL United Kingdom

london@wilsongunn.com Tel: 0203 178 2767 Fax: 0203 178 5823

BIRMINGHAM OFFICE

Charles House 148/9 Great Charles Street Birmingham B3 3HT United Kingdom

birmingham@wilsongunn.com Tel: 0121 236 1038 Fax: 0121 233 2875

CHESTERFIELD OFFICE

Tapton Park Innovation Centre Brimington Road Tapton Chesterfield S41 0TZ United Kingdom

chesterfield@wilsongunn.com Tel: 01246 541 903 Fax: 01246 230 055